20 July 2020: OIA response: medicines funded for the treatment of multiple sclerosis

20 July 2020

Dear [name and contact details withheld]

REQUEST FOR INFORMATION

Thank you for your email of 23 June 2020 in which you request data on treatments funded for multiple sclerosis in the last 15 years.

The following table lists only those funded medicines that were first listed specifically to treat multiple sclerosis. The table does not include medicines funded for multiple indications, that may be used to treat multiple sclerosis as well as other conditions. PHARMAC does not list all pharmaceuticals by indication, as many pharmaceuticals have multiple indications, therefore we have not been able to search all possible multiple sclerosis treatments.

Name of funded medicine

Year first listed by PHARMAC in the Pharmaceutical Schedule

Dimethyl fumarate

2016

Fingolimod

2014

Natalizumab

2014

Ocrelizumab

2019

Teriflunomide

2016

Glatiramer acetate

2000

Interferon beta-1-alpha

2000

Interferon beta-1-beta

2000

You can find full listings of funded medicines for past years in their Pharmaceutical Schedules.  Copies of these schedules from April 2002 are available under the Schedule Archive on the PHARMAC website:
https://pharmac.govt.nz/pharmaceutical-schedule/community-section-b/

Currently funded medicines can be tracked individually on the on-line Pharmaceutical Schedule, on the website: https://schedule.pharmac.govt.nz/ScheduleOnline.php (external link)

In the Pharmaceutical Schedule, medicines for multiple sclerosis are listed under the multiple sclerosis treatments and other multiple sclerosis treatments sub-headings, under the Nervous System category.

We trust that this information answers your queries.

Yours sincerely

 

Rachel Read
Manager, Policy and Government Services